EXHIBIT A

               GIVEN IMAGING ANNOUNCES THIRD QUARTER 2002 RESULTS

              - Fourth consecutive quarter of increased revenues -

Yoqneam,  Israel,  October 30, 2002 - Given  Imaging Ltd.  (NASDAQ:GIVN),  today
announced  revenues of $7.5 million for the third quarter of 2002,  representing
an  increase of 480% over  revenues in the third  quarter of 2001 and the fourth
consecutive quarter of increased revenues. The third quarter also represents the
fourth  full  quarter of sales for the Company  for both the U.S.  and  European
markets  following FDA clearance of the Given(R)  Diagnostic  Imaging  system in
August 2001 and clearance to affix the CE-mark in Europe in May 2001.

On a geographic basis,  sales of the Given System in the United States accounted
for 58% of quarterly revenues.  Seasonality negatively affected revenues both in
Europe and the United  States.  The  geographic  breakdown of third quarter 2002
revenues is as follows:

(millions of U.S. dollars)

United States     $4.3

Europe            $1.5

ROW               $1.7

Third Quarter 2002 Financials

Gross profit for the third  quarter was 58.7% of revenues,  compared to 54.4% in
the second quarter of 2002. Net loss for the third quarter was $4.0 million,  or
$0.16 per share,  compared to a net loss of $4.9 million, or $0.20 per share, in
the second quarter of 2002.

First Nine Month Results 2002

Revenues  totaled $19.9 million for the first nine months of 2002.  Gross profit
was 55.4% of revenues.  Operating expenses were $26.0 million.  Net loss for the
first nine months of 2002 was $14.6 million.

Third Quarter Highlights

"Our third quarter sales reflect continued  penetration of the Given System into
the markets and our broad global coverage that reduced the impact of seasonality
in certain markets," said Gavriel Meron, President and CEO of Given Imaging.

During the third quarter, Given Imaging accomplished the following milestones:

     -    Sold more than 6,500 M2A capsules,  of which more than 4,600 represent
          reorders.  Cumulatively,  more than 21,000 M2A capsules have been sold
          to date.
<PAGE>
     -    Cumulative  deliveries  of the  Given  System  reached  more  than 780
          systems, with more than 350 systems installed in the United States.

     -    Received  notification of insurance  coverage  statements from Horizon
          Blue Cross Blue Shield of New  Jersey.  In late  September,  Riverbend
          Government  Benefits  Administrator,  a Medicare Fiscal  Intermediary,
          issued a coverage  statement  for capsule  endoscopy  performed  in an
          outpatient  hospital  setting for the states of New Jersey,  Tennessee
          and in Rural Health Clinics in 44 other states.  Currently,  more than
          35 million  individuals in the United States have reimbursable  access
          to the Given Diagnostic System,  mainly for disorders  associated with
          gastrointestinal   bleeding   from  sources   unidentified   by  other
          diagnostic  methods.  Coverage for other  indications  continues to be
          reimbursed on a case-by-case basis.

     -    Sponsorship  by the American  Society for  Gastrointestinal  Endoscopy
          (ASGE) of an inaugural  Continuing  Medical  Education (CME) course on
          Capsule Endoscopy.

     -    Publication   of  several   studies  in   peer-reviewed   publications
          demonstrating the benefits of capsule  endoscopy  including a study in
          Gastrointestinal Endoscopy (September 2002, Volume 56, Number 3) which
          concluded that the M2A capsule  identified small  intestinal  bleeding
          sites beyond the range of push  enteroscopy.  The study also concluded
          that capsule endoscopy provides  excellent  visualization of the small
          intestine,  and is well  tolerated and safe. A second study in Disease
          Management  (Volume 5, Number 3, 2002) by  investigators in the Office
          of Health Policy and Clinical Outcomes at Thomas Jefferson University,
          Philadelphia,  concluded  that  the M2A  capsule  endoscope  offers  a
          potential  net cost  savings  through  earlier  diagnosis  of  obscure
          intestinal  bleeding.  A third study appears in the September issue of
          Endoscopy (2002; 34 (9): 685 - 689) and concludes that the M2A capsule
          has a significantly  superior  diagnostic  yield when compared to push
          enteroscopy.

     -    The Given System was granted regulatory approval in two major Far East
          markets,  China and South Korea,  where we appointed  distributors  11
          months and 8 months ago, respectively.

Recent Events

The Company recently participated in three scientific  conferences at which more
than 40 clinical  presentations,  21 lectures  and an  off-site  symposium  took
place, demonstrating the superiority of capsule endoscopy to traditional methods
for diagnosing disorders of the small intestine. Conferences were:

     The American  College of  Gastroenterologists  (ACG) held October  18-23 in
     Seattle  attended  by more than 3,000  gastroenterologists  from the United
     States.  Fifteen  poster  and 6 oral  presentations  were  made on  capsule
     endoscopy.

<PAGE>
     United European  Gastroenterology Week (UEGW) held October 19-23 in Geneva,
     Switzerland and was attended by more than 3,000 gastroenterologists, mainly
     from Europe. At this conference  twenty-five clinical trials were presented
     including more than 900 patients.

     Australian Gastro Week (AGW) held October 13-20.

Fifteen  presentations on capsule  endoscopy were presented,  and an M2A Capsule
Endoscopy Symposium with 80 attendees was held.

Third Quarter Webcast Information

Given Imaging will host a live webcast tomorrow,  Thursday, October 31, 2002, at
10:00 am  Eastern  Time  (5:00 pm Israel  time) to discuss  third  quarter  2002
results.  The  presentation  will  be  webcast  through  the  Company's  website
www.givenimaging.com and will be available for rebroadcast on the website for 30
days.

About Given Imaging

Given  Imaging  develops,  produces and markets the Given(R)  Diagnostic  System
featuring the M2A(R) Capsule Endoscope,  the only non-invasive method for direct
visualization  of the  entire  small  intestine.  The system  uses a  disposable
miniature video camera  contained in a capsule which is ingested by the patient.
The M2A capsule passes naturally through the digestive tract,  transmitting high
quality color images,  without interfering with the patient's normal activities.
The  system  received  clearance  from  the  FDA in  August  2001  and  received
permission  to affix  the CE mark in May  2001.  Distribution  channels  for the
system have been  established in more than 40 countries  worldwide.  The M2A has
been utilized to diagnose a range of diseases of the small  intestine  including
Crohn's Disease,  Celiac disease and other malabsorption  disorders,  benign and
malignant tumors of the small intestine, vascular disorders,  medication related
small bowel injury,  as well as a range of pediatric small bowel disorders.  For
more information, visit http://www.givenimaging.com.

This press release contains  forward-looking  statements,  including projections
about our business,  within the meaning of Section 27A of the  Securities Act of
1933 and  Section  21E of the  Securities  Exchange  Act of 1934.  For  example,
statements  in the  future  tense,  words  such as  "anticipates,"  "estimates,"
"expects,"  "intends,"  "plans,"  "believes,"  "intends"  and words and terms of
similar  substance used in connection with any discussion of future operating or
financial   performance   identify  such   forward-looking   statements.   Those
forward-looking  statements are not guarantees of future  performance and actual
results could differ  materially  from our current  expectations  as a result of
numerous  factors,  including  but not  limited  to the  following:  changes  in
regulatory  environment,  our success in implementing  our sales,  marketing and
manufacturing  plan,  protection and validity of patents and other  intellectual
property  rights,   the  impact  of  currency  exchange  rates,  the  effect  of
competition  by  other  companies,   the  outcome  of  future  litigation,   the
reimbursement  policies  for  our  product  from  healthcare  payors,  quarterly
variations in operating  results,  and other risks disclosed in our filings with
the U.S. Securities Exchange Commission.

                                      # # #

                            (Financial tables follow)

<PAGE>
              Given Imaging Ltd. and its Consolidated Subsidiaries
                           Consolidated Balance Sheets
                    U.S. $ in thousands except per share data

                                                  December 31,     September 30,
                                                      2001             2002
                                                  ------------     ------------
                                                    (Audited)       (Unaudited)

Assets


Cash and cash equivalents                               $61,230          $42,508
Current assets                                            7,729           15,435
                                                      ---------        ---------

Total current assets                                     68,959           57,943

 Fixed assets, net                                        5,104            9,183

 Other assets, net                                        1,860            2,378
                                                      ---------        ---------

 Total Assets                                           $75,923          $69,504
                                                      =========        =========


Liabilities and shareholders' equity

 Current liabilities                                     5,875             8,777
 Deferred revenue                                          193               570
                                                      ---------        ---------

 Total current liabilities                               6,068             9,347

 Long-term liabilities                                     522               788

 Minority interest                                           -             2,209

 Shareholders' equity                                   69,333            57,160
                                                      ---------        ---------

Total liabilities and shareholders' equity             $75,923           $69,504
                                                      =========        =========

<PAGE>
              Given Imaging Ltd. and its Consolidated Subsidiaries
                      Consolidated Statements Of Operations
                    U.S. $ in thousands except per share data


<TABLE>
<CAPTION>
                                                    Nine month period           Three month period
                                                    ended September 30,          ended September 30,
                                                -----------   -----------   --------------------------
                                                   2001          2002           2001          2002
                                                -----------   -----------   -----------    -----------
                                                (Unaudited)   (Unaudited)   (Unaudited)    (Unaudited)
<S>                                             <C>           <C>           <C>            <C>
Revenues                                            $1,256        $19,854        $1,256         $7,459

Cost of revenues                                      (759)        (8,855)         (759)        (3,081)
                                                -----------   ------------   -----------    -----------

Gross profit                                           497         10,999           497          4,378

Research and development costs                      (4,032)        (6,570)       (1,464)        (2,261)
Marketing expenses                                  (7,565)       (16,111)       (3,272)        (5,287)
General and administrative expenses                 (1,599)        (3,284)         (693)          (970)
                                                -----------   ------------   -----------    -----------

Operating loss                                     (12,699)       (14,966)       (4,932)        (4,140)

Financing income, net                                  506          1,111           133            105
Other income (expenses)                                  -           (707)            -             20
                                                -----------   ------------   -----------    -----------

Net loss before minority share                     (12,193)       (14,562)       (4,799)        (4,015)

Minority share in (profits) loss of subsidiary           -            (53)            -              65
                                                -----------   ------------   -----------    -----------

Net loss                                         $ (12,193)     $ (14,615)     $ (4,799)      $ (3,950)
                                                ===========   ============   ===========    ===========

 Basic and diluted loss per Ordinary Share          $(1.60)        $(0.58)       $(0.62)        $(0.16)
                                                ===========   ============   ===========    ===========

Weighted average number of Ordinary Shares
outstanding used in basic and diluted loss
per Ordinary Share calculation                    8,807,490     25,144,913     8,814,090     25,174,913
                                                ===========   ============   ===========    ===========
</TABLE>